Population pharmacokinetics of tacrolimus and CYP3A5-driven variability: implications for model-informed dose individualization in pediatric renal transplant recipients.

Xajil-Ramos LY, Gándara-Mireles JA, Guerra-García M, Rosales RJV, Toledo AMR, Ocaña-Garrido DS, Lares-Asseff I, Cóbar O, Soveranis SM, Patrón-Romero L, Almanza-Reyes H, Lou-Meda R

Open source

DOI
10.1186/s40360-026-01157-5
Published
2026 Jun 13
Container
BMC pharmacology & toxicology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s40360-026-01157-5,
  title = {Population pharmacokinetics of tacrolimus and CYP3A5-driven variability: implications for model-informed dose individualization in pediatric renal transplant recipients.},
  author = {Xajil-Ramos LY and Gándara-Mireles JA and Guerra-García M and Rosales RJV and Toledo AMR and Ocaña-Garrido DS and Lares-Asseff I and Cóbar O and Soveranis SM and Patrón-Romero L and Almanza-Reyes H and Lou-Meda R},
  year = {2026},
  journal = {BMC pharmacology \& toxicology},
  doi = {10.1186/s40360-026-01157-5},
  url = {https://doi.org/10.1186/s40360-026-01157-5}
}

RIS

TY  - JOUR
TI  - Population pharmacokinetics of tacrolimus and CYP3A5-driven variability: implications for model-informed dose individualization in pediatric renal transplant recipients.
AU  - Xajil-Ramos LY
AU  - Gándara-Mireles JA
AU  - Guerra-García M
AU  - Rosales RJV
AU  - Toledo AMR
AU  - Ocaña-Garrido DS
AU  - Lares-Asseff I
AU  - Cóbar O
AU  - Soveranis SM
AU  - Patrón-Romero L
AU  - Almanza-Reyes H
AU  - Lou-Meda R
PY  - 2026
JO  - BMC pharmacology & toxicology
DO  - 10.1186/s40360-026-01157-5
UR  - https://doi.org/10.1186/s40360-026-01157-5
ER  - 

APA

LY, X., JA, G., M, G., RJV, R., AMR, T., DS, O., I, L., O, C., SM, S., L, P., H, A., & R, L. (2026). Population pharmacokinetics of tacrolimus and CYP3A5-driven variability: implications for model-informed dose individualization in pediatric renal transplant recipients.. BMC pharmacology & toxicology. https://doi.org/10.1186/s40360-026-01157-5

Source records